

Table S1 Modalities of treatment in patients with grade 4 RCC

Characteristic	Value
Type of nephrectomy, n (%)	
Laparotomy	
Nephrectomy	67 (43.5)
Laparoscopy	
Nephrectomy	81 (52.6)
Partial nephrectomy	6 (3.9)
Targeted therapies (n=46), n (%)	
Sunitinib	11 (7.1)
Sorafenib	11 (7.1)
Axitinib	2 (1.3)
Sunitinib + sorafenib	1 (0.6)
Sorafenib + axitinib	1 (0.6)
Unknown§	20 (13.0)
Immunotherapy (n=2), n (%)	
Interferon α	2 (1.3)
Radiotherapy	1 (0.6)

§, loss of clinical or follow-up data. RCC, renal cell carcinoma.

Table S2 Detailed adjunctive therapy and response of grade 4 RCC patients

Systemic treatment	Number of patients	Proportion of treatment subset, %
Sunitinib (n=13)		
CR	4	30.8
PR	1	7.7
SD	1	7.7
PD	7	53.8
Sorafenib (n=12)		
CR	2	16.7
PR	3	25.0
SD	1	8.3
PD	6	50.0
Axitinib (n=2)		
CR	1	50.0
PD	1	50.0
Sunitinib + sorafenib (n=1)		
SD	1	100.0
Sorafenib + axitinib (n=1)		
PD	1	100.0
Interferon α (n=2)		
CR	1	50.0
SD	1	50.0
Radiotherapy		
PD	1	100.0

CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; RCC, renal cell carcinoma.